Endocyte: Clinical Trials

15 trials sponsored by Endocyte, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 3 terminated, 2 active not recruiting. 15 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 115Completed 10, Terminated 3, Active not recruiting 2
Phase 21Active not recruiting 1

Follow Endocyte: new trials by email

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
225^Ac-PSMA-617, 68^Ga-PSMA-11 - Prostatic Neoplasms, Castration-Resistant
Phase 1Active not recruitingEndocyte1012021-04-012026-04-30
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
177Lu-PSMA-617 - Prostatic Neoplasms
Phase 1 / Phase 2Active not recruitingPeter MacCallum Cancer Centre, Australia202020-08-062024-11-08
Imaging Activated Macrophages in the Lungs
Ga-EC2115 - COPD
Phase 1TerminatedVanderbilt University Medical Center132018-11-292021-08-11
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
EC1456, 99mTc-Etarfolatide - Ovary Cancer
Phase 1CompletedEndocyte32017-01-242019-02-07
Phase 1 of EC1169 In Patients With Recurrent MCRPC
EC1169, EC0652 - Prostate Cancer
Phase 1CompletedEndocyte402014-05-012019-02-07
A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)
Vintafolide - Solid Tumor
Phase 1TerminatedEndocyte32014-02-012015-02-10
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
EC1456 and EC20 - Solid Tumors, Non Small Cell Lung Carcinoma
Phase 1CompletedEndocyte932013-10-012019-02-07
Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers
Etarfolatide (EC20) - Healthy
Phase 1CompletedEndocyte232013-04-012014-07-29
A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)
Vintafolide, Carboplatin, Paclitaxel - Advanced Cancer
Phase 1TerminatedEndocyte372012-12-012015-02-10
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
EC0489, Injection, EC20 - Cancer
Phase 1CompletedEndocyte652009-04-012012-08-08
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors
EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate), 99mTC-EC20 (Folic acid-technetium 99m conjugate) - Cancer
Phase 1CompletedEndocyte772007-02-012012-03-09
Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)
Vintafolide IV Bolus, Vintafolide IV Infusion - Cancer
Phase 1CompletedEndocyte322006-03-012014-12-19
Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC) - Cancer
Phase 1CompletedEndocyte132005-09-012012-03-09
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
Tc 99m EC20 - Ovarian Cancer, Endometrial Cancer
Phase 1CompletedEndocyte122001-08-012023-06-22
Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients
Tc 99m EC20 - Ovarian Cancer, Healthy Volunteers
Phase 1CompletedEndocyte82000-08-012023-06-22

Conditions studied

Neoplasms (5)  ·  Ovarian Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Neoplasm Metastasis (2)  ·  Recurrence (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Endometrial Neoplasms (1)  ·  Genital Diseases, Male (1)  ·  Genital Neoplasms, Male (1)  ·  Neoplasms by Site (1)  ·  Prostatic Diseases (1)  ·  Prostatic Neoplasms, Castration-Resistant (1)  ·  Pulmonary Disease, Chronic Obstructive (1)  ·  Urogenital Neoplasms (1)

Interventions

EC145 (2)  ·  Folic Acid (2)  ·  (225)Ac-PSMA-617 (1)  ·  Carboplatin (1)  ·  EC 0489 (1)  ·  EC0225 (1)  ·  GPI0100 (1)  ·  Interferon-alpha (1)  ·  Interleukin-2 (1)  ·  Introns (1)  ·  Leucovorin (1)  ·  Paclitaxel (1)  ·  Pluvicto (1)  ·  WW Domain-Containing Oxidoreductase (1)  ·  aldesleukin (1)

Countries

United States (11)  ·  Australia (2)  ·  Canada (1)  ·  South Africa (1)

Top investigators

Alison Armour, MD (2)  ·  Alison Armour, MB ChB, BSc, MSc, MD, MRCP (1)  ·  Beth Safirstein, MD (1)  ·  Declan Murphy (1)  ·  James W. Fletcher, MD (1)  ·  John Violet (1)  ·  Michael S Hofman (1)  ·  Richard A Messmann, MD, MHS, BSc (1)  ·  Richard A Messmann, MD, MHS, MSc (1)  ·  Richard A. Messmann, MD, MHS, MSc (1)  ·  Timothy S Blackwell, MD (1)  ·  Wael Harb, MD (1)

Results publications

PMID 19837906, PMID 23032618, PMID 37891072